MASP-2 Inhibitors Target Lectin Pathway Initiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current complement inhibitors primarily target downstream components of the complement system, such as C5, which do not effectively inhibit the initiation of complement activation, leading to adverse effects in various disease states like myocardial infarction, stroke, and autoimmune disorders, where early intervention in the complement activation pathway is necessary.
Innovation Solution
Development of MASP-2 inhibitory agents, including antibodies and peptides, that specifically target the lectin-dependent complement pathway without affecting the classical pathway, thereby inhibiting MASP-2-dependent complement activation and reducing tissue damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If downstream complement inhibitors (e.g., C5 antibodies) are used, then complement-mediated tissue injury is reduced, but the initiation of complement activation is not inhibited, leading to adverse effects in disease states
Solution Approach 1:
The patent extracts and targets the specific initiation step of the lectin pathway by developing MASP-2 inhibitory agents. This isolates the problematic initiation mechanism from the overall complement system, allowing selective inhibition of lectin pathway activation while preserving classical pathway functionality and other immune defenses.
Solution Approach 2:
The patent introduces MASP-2 inhibitory agents as intermediary substances that specifically block the lectin pathway initiation step. These agents act as mediators between the lectin pathway components (MBL, ficolins) and the downstream complement cascade, preventing harmful activation without affecting other immune mechanisms.
2Object-affected harmful factors
If MASP-2 inhibitory agents are used to selectively inhibit the lectin pathway, then adverse effects are reduced while preserving classical pathway functionality, but device complexity increases
Solution Approach 1:
The patent applies local quality by creating inhibitors with specific targeting properties - MASP-2 inhibitory agents are designed to bind selectively to MASP-2 in the lectin pathway while leaving other complement components untouched. This localized inhibition approach provides precision therapy that addresses specific pathological mechanisms without broad suppression of the complement system.
3Reliability
If early intervention in the complement activation pathway is implemented, then protective immune response is maintained, but downstream complement components remain active causing potential damage
Solution Approach 1:
The patent segments the complement inhibition strategy by targeting only the lectin pathway initiation step through MASP-2 inhibition. This segmentation allows the protective aspects of complement activation to proceed through the classical pathway while blocking the harmful lectin pathway initiation, effectively dividing the complement system's functions for selective modulation.
Data Source
AI summary
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.